Bristol-Myers Squibb expects strong 2026 revenue growth driven by key drugs and upcoming ASCO data.

Bristol-Myers Squibb is on track to meet the higher end of its 2026 revenue and earnings guidance, largely due to strong sales of its key drugs Breyanzi, Camzyos, and Reblozyl, which grew 42.2% year-over-year to $1.28 billion in Q1. The company will also present full data on experimental drugs izalontamab brengitecan and pumitamig at ASCO 2026, potentially boosting its pipeline. These factors contribute to an attractive risk/reward profile for income-focused investors, supporting confidence in the company's future growth prospects.